SEC Tracker
Get the app

AVROBIO TECX

AVROBIO FY 2022: net loss $105.9M; diluted EPS −$4.57

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers AVROBIO reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$105.9MAgainst −$119.1M in FY 202110-K income statement, on EDGAR
  2. Diluted EPS−$4.57Against −$5.25 in FY 2021. Split-adjusted, as the tables show it; the filing reported −$2.4210-K income statement, on EDGAR
  3. Cash and cash equivalents$92.6M−51% from $189.6M in FY 202110-K balance sheet, on EDGAR
  4. Cash from operations−$97.2MAgainst −$98.0M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when AVROBIO files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  2. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  3. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  4. Lifecore Biomedical LFCR public float $223M, Jun 30, 2025
  5. Annexon ANNX public float $244M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.